Publications and Patents

 

Avalia’s patents and publications describe the novel composition of matter and use of our natural killer T (NKT) cell  agonists for the treatment and prevention of cancer and infectious disease. Our patents provide coverage in key pharmaceutical markets around the world.

Publications –

Nature Scientific Reports 2017:

Glycolipid-peptide conjugate vaccines enhance CD8+ T cell responses against human viral proteins

M. Speir, A. Authier-Hall, C. R. Brooks, K. J. Farrand, B. J. Compton, R. J. Anderson, A. Heiser, T. L. Osmond, C. W. Tang, J. A. Berzofsky, M. Terabe, G. F. Painter, I. F. Hermans*, and R. Weinkove*

Click to view full article

ACS Chemical Biology 2017:

Augmenting influenza-specific T cell memory generation with a natural killer T cell-dependent glycolipid-peptide vaccine

R. J. Anderson, J. Li, L. Kedzierski, B. J. Compton, C. M. Hayman, T. L. Osmond, C. W. Tang, K. J. Farrand,  H. F. Koay, C. F. D. S. S. E. Almeida, L. R. Holz, G. M. Williams, M. A. Brimble, Z. Wang, M. Koutsakos,  K. Kedzierska, D. I. Godfrey, I. J. Hermans, S. J. Turner* and G. F. Painter*

Chemical Science 2015:

NKT cell­-dependent glycolipid­-peptide vaccines with potent anti­-tumour activity  

R. J. Anderson,  B. J. Compton,  C. W. Tang, A. Authier-Hall, C. M. Hayman, G. W. Swinerd, R. Kowalczyk, P. Harris, M. A. Brimble, D. S. Larsen, O. Gasser, R. Weinkove, I. F. Hermans* and G. F. Painter*

Click to view full article

Nature Chemical Biology 2014:

A self-adjuvanting vaccine induces cytotoxic T lymphocytes that suppress allergy

R. J. Anderson, C. W. Tang, N. J. Daniels, B. J. Compton, C. M. Hayman, K. A. Johnston, D. A. Knight, O. Gasser, H. C. Poyntz, P. M. Ferguson, D. S. Larsen, F. Ronchese, G. F. Painter* and I. F. Hermans*

Click to view full article

US granted Patents –